Skip to main content

Table 1 Prognostic value of Glypican family genes in The Cancer Genome Atlas database

From: Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Gene No. of events (%) MST (days) Crude HR
95% CI
Crude
P value
Adjusted HR
95% CIa
Adjusted
P valuea
GPC1
 Low 36/56(64.3%) 518 1   1  
 High 33/56(58.9%) 511 0.986(0.610–1.594) 0.955 1.120 (0.661–1.896) 0.674
GPC2
 Low 41/56(73.2%) 481 1   1  
 High 28/56(50.0%) 634 0.589(0.362–0.959) 0.031 0.449(0.258–0.782) 0.005
GPC3
 Low 38/56(67.9%) 473 1   1  
 High 31/56(55.4%) 614 0.568(0.349–0.925) 0.021 0.531(0.309–0.914) 0.022
GPC4
 Low 35/56(62.5%) 517 1   1  
 High 34/56(60.7%) 592 1.066(0.659–1.723) 0.794 1.252(0.744–2.105) 0.397
GPC5
 Low 35/56(62.5%) 485 1   1  
 High 34/56(60.7%) 593 0.577(0.351–0.948) 0.028 0.525(0.306–0.902) 0.020
GPC6
 Low 37/56(66.1%) 485 1   1  
 High 32/56(57.1%) 603 0.647(0.393–1.063) 0.083 0.891(0.501–1.585) 0.693
  1. Abbreviations: MST median survival time, HR hazard ratio, CI confidence interval
  2. aAdjusted for histologic grade, targeted molecular therapy, radiation therapy and radical resection